These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cleaved Form of Osteopontin in Urine as a Clinical Marker of Lupus Nephritis. Kitagori K; Yoshifuji H; Oku T; Sasaki C; Miyata H; Mori KP; Nakajima T; Ohmura K; Kawabata D; Yukawa N; Imura Y; Murakami K; Nakashima R; Usui T; Fujii T; Sakai K; Yanagita M; Hirayama Y; Mimori T PLoS One; 2016; 11(12):e0167141. PubMed ID: 27992535 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-35 as a New Biomarker of Renal Involvement in Lupus Nephritis Patients. He D; Liu M; Liu B Tohoku J Exp Med; 2018 Apr; 244(4):263-270. PubMed ID: 29576585 [TBL] [Abstract][Full Text] [Related]
6. Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis. Adhya Z; El Anbari M; Anwar S; Mortimer A; Marr N; Karim MY Lupus; 2019 May; 28(6):713-721. PubMed ID: 31046570 [TBL] [Abstract][Full Text] [Related]
7. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Wirestam L; Enocsson H; Skogh T; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace D; Isenberg DA; Rahman A; Merrill J; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma A; Ruiz-Irastorza G; Lim S; Kalunian K; Inanc M; van Vollenhoven R; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken C; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C J Rheumatol; 2019 May; 46(5):492-500. PubMed ID: 30647177 [TBL] [Abstract][Full Text] [Related]
9. Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus. Wirestam L; Saleh M; Svensson C; Compagno M; Zachrisson H; Wetterö J; Sjöwall C Lupus; 2021 Jul; 30(8):1244-1253. PubMed ID: 33957796 [TBL] [Abstract][Full Text] [Related]
10. Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations. Abdulahad DA; Westra J; Bijzet J; Dolff S; van Dijk MC; Limburg PC; Kallenberg CG; Bijl M Arthritis Res Ther; 2012 Aug; 14(4):R184. PubMed ID: 22892043 [TBL] [Abstract][Full Text] [Related]
11. Monocyte chemoattractant protein-1 as a marker of systemic lupus erythematosus: an observational study. Živković V; Cvetković T; Mitić B; Stamenković B; Stojanović S; Radovanović-Dinić B; Jurišić V Rheumatol Int; 2018 Jun; 38(6):1003-1008. PubMed ID: 29181621 [TBL] [Abstract][Full Text] [Related]
12. Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus. Patyna S; Büttner S; Eckes T; Obermüller N; Bartel C; Braner A; Trautmann S; Thomas D; Geiger H; Pfeilschifter J; Koch A Prostaglandins Other Lipid Mediat; 2019 Oct; 144():106348. PubMed ID: 31301404 [TBL] [Abstract][Full Text] [Related]
13. Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis. Puapatanakul P; Chansritrakul S; Susantitaphong P; Ueaphongsukkit T; Eiam-Ong S; Praditpornsilpa K; Kittanamongkolchai W; Avihingsanon Y Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31597273 [TBL] [Abstract][Full Text] [Related]